Primary Biliary Cirrhosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Primary Biliary Cirrhosis - Pipeline Review, H2 2016

Primary Biliary Cirrhosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Primary Biliary Cirrhosis - Pipeline Review, H2 2016
Published Jul 13, 2016
90 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Primary Biliary Cirrhosis - Pipeline Review, H2 2016, provides an overview of the Primary Biliary Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis
- The report reviews pipeline therapeutics for Primary Biliary Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Primary Biliary Cirrhosis therapeutics and enlists all their major and minor projects
- The report assesses Primary Biliary Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Primary Biliary Cirrhosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline proje

  
Source:
Document ID
GMDHC8270IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Primary Biliary Cirrhosis Overview71
Therapeutics Development81
  Pipeline Products for Primary Biliary Cirrhosis Overview81
Primary Biliary Cirrhosis Therapeutics under Development by Companies91
Primary Biliary Cirrhosis Pipeline Products Glance104
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
  Unknown Stage Products131
Primary Biliary Cirrhosis Products under Development by Companies141
Primary Biliary Cirrhosis Companies Involved in Therapeutics Development1513
  AlbireoPharma151
  CymaBay Therapeutics, Inc.161
  Dr. Falk Pharma GmbH171
  Enanta Pharmaceuticals, Inc.181
  Genextra S.p.a.191
  GenKyoTex S.A.201
  GlaxoSmithKline Plc211
  MediGene AG221
  NGM Biopharmaceuticals, Inc.231
  Novartis AG241
  Shire Plc251
  TGV-Laboratories261
  Virobay Inc.271
Primary Biliary Cirrhosis Therapeutics Assessment289
  Assessment by Monotherapy Products281
  Assessment by Target292
  Assessment by Mechanism of Action312
  Assessment by Route of Administration332
  Assessment by Molecule Type352
Drug Profiles3733
  A-4250 Drug Profile372
  budesonide Drug Profile393
  EDP-305 Drug Profile421
  FFP-104 Drug Profile431
  GKT-831 Drug Profile443
  GSK-2330672 Drug Profile471
  Hep-114 Drug Profile481
  LJN-452 Drug Profile491
  maralixibat chloride Drug Profile503
  MBX-8025 Drug Profile533
  NGM-282 Drug Profile562
  obeticholic acid Drug Profile589
  RhuDex Drug Profile672
  VBY-825 Drug Profile691
Primary Biliary Cirrhosis Dormant Projects701
Primary Biliary Cirrhosis Product Development Milestones7118
  Featured News &Press Releases711
    May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)711
    May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC721
    May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016732
    Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL751
    Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC761
    Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016772
    Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn s Disease with anti-CD40 Monoclonal Antibody791
    Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC801
    Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015801
    Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis811
    Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015821
    Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting832
    Aug 31, 2015: FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis851
    Jun 29, 2015: Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis861
    Apr 13, 2015: Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015872
Appendix892
  Methodology891
  Coverage891
  Secondary Research891
  Primary Research891
  Expert Panel Validation891
  Contact Us891
  Disclaimer901

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Primary Biliary Cirrhosis - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Primary-Biliary-Cirrhosis-Pipeline-Review-H2-2016-2088-16171>
  
APA:
Global Markets Direct - Market Research. (2016). Primary Biliary Cirrhosis - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Primary-Biliary-Cirrhosis-Pipeline-Review-H2-2016-2088-16171>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.